Palatin Technologies, Inc. (PTN): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTN POWR Grades
- PTN scores best on the Sentiment dimension, with a Sentiment rank ahead of 85.79% of US stocks.
- The strongest trend for PTN is in Value, which has been heading up over the past 151 days.
- PTN's current lowest rank is in the Stability metric (where it is better than 7.93% of US stocks).
PTN Stock Summary
- With a price/sales ratio of 18.91, PALATIN TECHNOLOGIES INC has a higher such ratio than 93.71% of stocks in our set.
- As for revenue growth, note that PTN's revenue has grown 739.73% over the past 12 months; that beats the revenue growth of 98.55% of US companies in our set.
- The volatility of PALATIN TECHNOLOGIES INC's share price is greater than that of 97.84% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to PALATIN TECHNOLOGIES INC are ANGN, BGRY, LCTX, NBTX, and XBIO.
- PTN's SEC filings can be seen here. And to visit PALATIN TECHNOLOGIES INC's official web site, go to www.palatin.com.
PTN Valuation Summary
- PTN's price/earnings ratio is -1.1; this is 104.98% lower than that of the median Healthcare stock.
- PTN's price/sales ratio has moved down 4335 over the prior 243 months.
Below are key valuation metrics over time for PTN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PTN | 2023-01-30 | 19.1 | 4.9 | -1.1 | -0.6 |
| PTN | 2023-01-27 | 19.1 | 4.9 | -1.1 | -0.6 |
| PTN | 2023-01-26 | 19.4 | 5.0 | -1.1 | -0.6 |
| PTN | 2023-01-25 | 19.8 | 5.1 | -1.2 | -0.6 |
| PTN | 2023-01-24 | 20.7 | 5.3 | -1.2 | -0.7 |
| PTN | 2023-01-23 | 20.9 | 5.4 | -1.2 | -0.7 |
PTN Growth Metrics
- The year over year cash and equivalents growth rate now stands at -45.05%.
- The 2 year price growth rate now stands at -15.23%.
- Its 2 year revenue growth rate is now at -98.55%.
The table below shows PTN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 2.178629 | -32.08045 | -37.34109 |
| 2022-06-30 | 1.468457 | -29.92275 | -36.1983 |
| 2022-03-31 | 0.872912 | -30.74029 | -37.36496 |
| 2021-12-31 | 0.745556 | -24.75327 | -35.46304 |
| 2021-09-30 | 0.259445 | -32.88457 | -36.76834 |
| 2021-06-30 | -0.188597 | -22.64799 | -33.59649 |
PTN Stock Price Chart Interactive Chart >
PTN Price/Volume Stats
| Current price | $4.07 | 52-week high | $13.00 |
| Prev. close | $3.98 | 52-week low | $2.14 |
| Day low | $3.92 | Volume | 50,700 |
| Day high | $4.21 | Avg. volume | 106,300 |
| 50-day MA | $3.60 | Dividend yield | N/A |
| 200-day MA | $6.15 | Market Cap | 37.99M |
Palatin Technologies, Inc. (PTN) Company Bio
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
Latest PTN News From Around the Web
Below are the latest news stories about PALATIN TECHNOLOGIES INC that investors may wish to consider to help them evaluate PTN as an investment opportunity.
Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney DiseasePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2b clinical trial with the melanocortin agonist, bremelanotide. The BREAKOUT Study, entitled "A Phase 2b, Multicenter, Open-Label, Prospective Study of BREmelanotide in DiAbetic Kidney Disease to Assess the Efficacy in Reducing Urinary PrOtein and Maintaining Po |
Palatin Receives $4.7 Million of Non-Dilutive FundingPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has received approximately $4.7 million of non-dilutive funding through the New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program. |
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory ConditionsPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers in Immunology published a manuscript, "Pro-resolving and anti-arthritic Properties of the MC1 Selective Agonist PL8177", summarizing data demonstrating PL8177 provides therapeutic effects in inflammatory conditions, including arthritis. |
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales ResultsPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced preliminary fiscal second quarter ended December 31, 2022 Vyleesi® product sales results. Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). |
Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Palatin Technologies (PTN)Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Palatin Technologies (PTN - Research Report) today and set a price target of $50.00. The company's shares closed yesterday at $4.31.Higgins covers the Healthcare sector, focusing on stocks such as Palatin Technologies, SCYNEXIS, and Eiger Biopharmaceuticals. According to TipRanks, Higgins has an average return of 4.4% and a 30.58% success rate on recommended stocks. Palatin Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $60.00, representing a 1,292.11% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target. |
PTN Price Returns
| 1-mo | 62.80% |
| 3-mo | -17.94% |
| 6-mo | -41.52% |
| 1-year | -61.24% |
| 3-year | -74.95% |
| 5-year | -82.61% |
| YTD | 58.98% |
| 2022 | -79.98% |
| 2021 | -24.30% |
| 2020 | -13.60% |
| 2019 | 10.17% |
| 2018 | -17.35% |
Continue Researching PTN
Want to see what other sources are saying about Palatin Technologies Inc's financials and stock price? Try the links below:Palatin Technologies Inc (PTN) Stock Price | Nasdaq
Palatin Technologies Inc (PTN) Stock Quote, History and News - Yahoo Finance
Palatin Technologies Inc (PTN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...